Atalys has acquired precision moldmaker ROMOLD, Inc. of Rochester, New York. A.S. Freeman Advisors, LLC advised ROMOLD on this transaction. For more information please contact Tony Freeman. Anthony S. Freeman A.S. Freeman Advisors, LLC (917) 868-0772 tfreeman@asfreeman.com asfreeman.com
News/Reports
Tony Freeman will be attending MPO Summit 2022 and Device Talks West 2022, and welcomes the opportunity to meet with colleagues. Schedule: MPO Summit in Austin, TX on Tuesday, October 18 – at Austin Marriot Downtown Device Talks West in Santa Clara on WednesdayOctober 19 – at Santa Clara Convention Center Get in touch with me at (917) 878-0772 or by email at tfreeman@asfreeman.com to set up a time to get together.
My latest piece for MPO Magazine discusses business strategies for the medical device supply chain in response to two trends: the rise of reliance on contract manufacturers vs OEMs, and supply chain consolidation.
Two strategies have emerged: the integrated contract manufacturer approach, and the specialist niche approach. I discuss the advantages and disadvantages of each, and opportunities for strategic expansion.
My annual report on Global Trends in Medtech for 2022 is now available.
I presented Part 1 and Part 2 for MPO at their webinar series on March 1 & 2, 2022, followed by a panel discussion on March 3. MPO will archive the webinar segments for one year (free registration may be required).
I am presenting at MPO’s “Global Trends in Medtech 2022: OEMs and the Supply Chain” webinar series on March 1, 2 & 3, 2022. Registration is free for this informative three-part series. SESSION 1: TUESDAY, MARCH 1 – 2:00 p.m. The OEM Landscape—Fundamental Change on the Horizon The OEM Landscape and Business Drivers How Big Is the Market? What’s the Growth Rate? The Impact of COVID and Lessons Learned A Slowly but Clearly Changing Business Model for OEM Are Limits on Medical Spending Starting to Appear? Four Most Significant Product Trends SESSION 2: WEDNESDAY, MARCH 2 – 2:00 p.m. OEM Product Trends Will Reshape the Supply Chain—Dethroning Current Kings Changing OEM Strategy Triggering a New Supply Chain Structure How Big Is the Supply Chain? What’s the Growth Rate? Myths Believed by Traditional Supply Chain Companies COVID, Automation, and LCCs Will Manufacturers of Non-Digital Products Survive? Which Supply Chain Companies Are Best Positioned to Prosper? SESSION 3: THURSDAY, MARCH 3 – 2:00 p.m. Panel Discussion of Medtech’s Global Trends The final portion of this three-part series will feature a panel of industry representatives discussing topics and points made during the first two sessions. Moderated by Tony Freeman, this candid conversation will look at factors impacting OEMs as well as the supply chain. The audience will be encouraged to pose questions to the panel as they look ahead as to what they expect in 2022 and beyond. REGISTER NOW AT MPO
Dear Colleague, I am pleased to announce the acquisition of Berg Manufacturing by Biomerics NLE. The Berg transaction notably extends Biomerics’ micromachining capabilities. A.S. Freeman Advisors advised Biomerics on the transaction. You can read the entire press release here. For more information on the medical device supply chain M&A market, please contact me at tfreeman@asfreeman.com or (917) 868-0772. Best regards, Tony Freeman
My latest, “Digital Devices, OEMs, and the Supply Chain: The End of the World as We Know It”, out today in MPO Magazine. Introduction: Even casual readers of OEM product websites and the device industry press are aware medical devices contain increasing amounts of digital technology. Putting numbers to the trend, recent Medtronic product announcements show 13 of 17 new products and 24 of 27 of planned products are digitally enabled. Of MPO’s Top 30 OEMs, 26 offer or plan to sell analytics or artificial intelligence products. Nine of the Top 30 offer or have announced robotic surgery devices. Another four are concentrating on digital products to enhance robotic systems. Driving these innovations are economics. Digitally capable, linked devices often produce superior outcomes to mechanical and electromechanical devices that have been the mainstays of OEM product lines for decades. Superior results often lead to lower cost per procedure, pleasing the governments and insurance companies worldwide that pay for healthcare. Read the entire article here, and please get in touch with any comments or questions.
In an April 21 press release Medtronic plc (NYSE:MDT) announced sharp revenue drops in comparison to 2019’s March and April results: Revenues in the United States declined 60% “over the last few weeks” with the exception of customer bulk purchases. The US represented 53% of Medtronic’s pre-COVID-19 sales. Western Europe has seen a 20 to 30% contraction vs. the same weeks last year. Western Europe represented 20% of Medtronic’s pre-COVID sales. China has seen a modest recovery. Mid-March revenues declined as much as 50% from the same period last year. Sales are up but still lag 20 to 40% below last year’s numbers. Medtronic also reports customers tightly managing inventories to conserve cash. To read the press release please visit http://newsroom.medtronic.com/news-releases/news-release-details/medtronic-provides-update-covid-19-pandemic-response-and-impact Please contact me at (917) 868-0772 or tfreeman@asfreeman.com with questions or comments. Stay well.